Are you over 18 and want to see adult content?
More Annotations
![A complete backup of northstarbattery.com](https://www.archivebay.com/archive5/images/1ebe410d-e4f7-4c6e-a081-8247eea614e3.png)
A complete backup of northstarbattery.com
Are you over 18 and want to see adult content?
![A complete backup of samariter-isenthal.ch](https://www.archivebay.com/archive5/images/6da8b18b-24dc-4d94-9748-79a8456455e1.png)
A complete backup of samariter-isenthal.ch
Are you over 18 and want to see adult content?
![A complete backup of innovationfiles.org](https://www.archivebay.com/archive5/images/78227443-481c-40c7-98ba-a4fedd0ae058.png)
A complete backup of innovationfiles.org
Are you over 18 and want to see adult content?
![A complete backup of theresurgent.com](https://www.archivebay.com/archive5/images/2953596f-c305-406e-b028-dd1d918f466c.png)
A complete backup of theresurgent.com
Are you over 18 and want to see adult content?
![A complete backup of internationalman.com](https://www.archivebay.com/archive5/images/a43352ad-a4f7-423f-8c8e-fed7cbe84237.png)
A complete backup of internationalman.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of allthingsvice.com](https://www.archivebay.com/archive/2e3a8b5d-6ca4-4d0a-8d01-96716e9caad7.png)
A complete backup of allthingsvice.com
Are you over 18 and want to see adult content?
![A complete backup of gretaundluis.com](https://www.archivebay.com/archive/5d948c01-3201-4d56-8252-1e53c141f382.png)
A complete backup of gretaundluis.com
Are you over 18 and want to see adult content?
![A complete backup of estetikinternational.com.tr](https://www.archivebay.com/archive/734d59fa-8e0a-4af3-80df-c4d0088639f4.png)
A complete backup of estetikinternational.com.tr
Are you over 18 and want to see adult content?
![A complete backup of hitrashmut.co.il](https://www.archivebay.com/archive/1f7ac903-8f5a-4234-a86b-4ed664087bdc.png)
A complete backup of hitrashmut.co.il
Are you over 18 and want to see adult content?
![A complete backup of autokonfigurator12.pl](https://www.archivebay.com/archive/2a05d9e1-c218-4787-9e9b-4888e8a99734.png)
A complete backup of autokonfigurator12.pl
Are you over 18 and want to see adult content?
![A complete backup of acordesdeviolao.com.br](https://www.archivebay.com/archive/5cd8fe6e-e2bb-4c5b-8214-ede45b5482af.png)
A complete backup of acordesdeviolao.com.br
Are you over 18 and want to see adult content?
![A complete backup of angst-verstehen.de](https://www.archivebay.com/archive/cafc91e6-34d5-4df4-ba2a-db9ede2a1191.png)
A complete backup of angst-verstehen.de
Are you over 18 and want to see adult content?
Text
DELIVERY METHOD
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
We count on the contributions of our talented team members who are committed to improving the lives of cancer patients. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission.NOVOCURE
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patientoutcomes.
SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR NOVOCURE ANNOUNCES LAUNCH OF MYLINK™ TO ENABLE PATIENT ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave of 30 U.S.patients Read More
PANCREATOLOGY PUBLISHES RESULTS OF THE PANOVA PHASE 2 about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVE ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancerDELIVERY METHOD
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
We count on the contributions of our talented team members who are committed to improving the lives of cancer patients. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission.NOVOCURE
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patientoutcomes.
SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR NOVOCURE ANNOUNCES LAUNCH OF MYLINK™ TO ENABLE PATIENT ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave of 30 U.S.patients Read More
PANCREATOLOGY PUBLISHES RESULTS OF THE PANOVA PHASE 2 about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVE ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. PerNOVOCURE
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patientoutcomes.
EXTERNAL FUNDING
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.ANNUAL REPORTS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. FIRST PATIENT ENROLLED IN NOVOCURE’S GLOBAL PHASE 3 TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the first patient has been NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More NOVOCURE (NVCR) OVERVIEW 4 • >40% growth in prescriptions for newly diagnosed GBM • $248M net revenues • Collaboration with Zai Lab in China • National reimbursement in Sweden NCCN GUIDELINES RECOMMEND NOVOCURE'S GBM THERAPY IN Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomideCAREERS AT NOVOCURE
Find at novocure. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals.WILCO GROENHUYSEN
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readinessLAUNCH PLANNER
Description: Senior Project Manager, Launch Excellence – Strategic Initiatives and Innovation JOB SUMMARY: The Senior Project Manager, Launch Excellence is responsible for successfully leading the global planning of new products and services. Responsibilities may also include local execution planning and support based on market needs. NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.ANNUAL REPORTS
annual reports. annual. reports. See our business highlights, and hear from our Executive Chairman William Doyle and CEO Asaf Danziger in our2020
NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNARCAREERS AT NOVOCURE
Shift Type. Reset. Senior Regulatory Affairs Specialist. Senior Regulatory Affairs Specialist Haifa, IL, 3508504 Regulatory/Safety Jun 1, 2021. Haifa, IL, 3508504. Regulatory/Safety. Full Time. Logistic and Office Administrator. Logistic and Office Administrator Haifa, IL, 3508504 Supply Chain Jun 1, 2021. RESULTS FROM STELLAR TRIAL OF TUMOR TREATING FIELDS WITH STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE’S OPTUNE® NOW AVAILABLE AT MORE THAN 600 CANCER Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe DIRECTOR, RISK OFFICER Description: JOB SUMMARY: The Director, Risk Officer is primarily responsible for risk management strategy development and execution, risk assessment and treatment, risk financing, management of property loss prevention and business continuity programs, and management of risk management information systems. The position will collaborate with internal clients in all areas and at all levels of NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.ANNUAL REPORTS
annual reports. annual. reports. See our business highlights, and hear from our Executive Chairman William Doyle and CEO Asaf Danziger in our2020
NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNARCAREERS AT NOVOCURE
Shift Type. Reset. Senior Regulatory Affairs Specialist. Senior Regulatory Affairs Specialist Haifa, IL, 3508504 Regulatory/Safety Jun 1, 2021. Haifa, IL, 3508504. Regulatory/Safety. Full Time. Logistic and Office Administrator. Logistic and Office Administrator Haifa, IL, 3508504 Supply Chain Jun 1, 2021. RESULTS FROM STELLAR TRIAL OF TUMOR TREATING FIELDS WITH STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE’S OPTUNE® NOW AVAILABLE AT MORE THAN 600 CANCER Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe DIRECTOR, RISK OFFICER Description: JOB SUMMARY: The Director, Risk Officer is primarily responsible for risk management strategy development and execution, risk assessment and treatment, risk financing, management of property loss prevention and business continuity programs, and management of risk management information systems. The position will collaborate with internal clients in all areas and at all levels ofABOUT US - NOVOCURE
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.INVESTOR RELATIONS
Request certificates. Enroll in eDelivery to receive shareholder materials electronically. Telephone inquiries: +1 (877) 373-6374 (US, Canada, Puerto Rico) +1 (781) 575-3100 (non-US) Written requests: By regular mail: Computershare. LEADERSHIP - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.DELIVERY METHOD
The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and more. The portable therapy is designed to be delivered continuously throughout the day and night, and to allow patients to go about their daily activities while receiving treatment. OPTUNE.COM.EXTERNAL FUNDING
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. Novocure considers a variety of factors when making funding decisions. Consistent with our commitment and policy to conduct business ethically, Novocure will only fund requests for activities orSEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.NOVOCURE
Novocure. Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. This site allows you to submit a proposal (s) seeking Independent Medical Educational Grants and CharitableContributions.
NOVOCURE’S OPTUNE® NOW AVAILABLE AT MORE THAN 600 CANCER Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe NOVOCURE ANNOUNCES LAUNCH OF MYLINK™ TO ENABLE PATIENT ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave of 30 U.S.patients Read More
NOVOCURE (NVCR) OVERVIEW 4 • >40% growth in prescriptions for newly diagnosed GBM • $248M net revenues • Collaboration with Zai Lab in China • National reimbursement in Sweden NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancerABOUT US - NOVOCURE
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.DELIVERY METHOD
The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and more. The portable therapy is designed to be delivered continuously throughout the day and night, and to allow patients to go about their daily activities while receiving treatment. OPTUNE.COM.SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.NOVOCURE
Novocure. Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. This site allows you to submit a proposal (s) seeking Independent Medical Educational Grants and CharitableContributions.
CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVEOPTUNE MEDICARE COVERAGENOVOCURE OPTUNE DEVICENOVOCURE ISRAELNOVOCURE LOCATIONSNOVOCURE MALVERN PANOVOCURE WIKIPEDIA ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancerABOUT US - NOVOCURE
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.DELIVERY METHOD
The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and more. The portable therapy is designed to be delivered continuously throughout the day and night, and to allow patients to go about their daily activities while receiving treatment. OPTUNE.COM.SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.NOVOCURE
Novocure. Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. This site allows you to submit a proposal (s) seeking Independent Medical Educational Grants and CharitableContributions.
CMS ESTABLISHES 2019 MONTHLY FEE SCHEDULE AMOUNT FOR ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS follows an announcement earlier this morning by the NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVEOPTUNE MEDICARE COVERAGENOVOCURE OPTUNE DEVICENOVOCURE ISRAELNOVOCURE LOCATIONSNOVOCURE MALVERN PANOVOCURE WIKIPEDIA ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. PerANNUAL REPORTS
annual reports. annual. reports. See our business highlights, and hear from our Executive Chairman William Doyle and CEO Asaf Danziger in our2020
OUR PIPELINE
The science of Tumor Treating Fields has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 20 years. We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancercells.
NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR NOVOCURE INITIATES PHASE 3 PIVOTAL TRIAL IN RECURRENT ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trialinitiated to
PATIENT FORWARD
patient. forward. Patients remain at the heart of the work we do every day. Patients’ health. Patients’ lives. Patients’ families and caregivers. They are what matters most to us, guiding us forward in our goal to deliver a completely different cancer therapy that could lengthen patient lives while maintaining their quality of life. NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More FIRST PATIENT ENROLLED IN NOVOCURE’S EF-33 PHASE 2 PILOT EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients NCCN GUIDELINES RECOMMEND NOVOCURE'S GBM THERAPY IN Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as RESULTS FROM STELLAR TRIAL OF TUMOR TREATING FIELDS WITH STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced NOVOCURE (NVCR) OVERVIEW 4 • >40% growth in prescriptions for newly diagnosed GBM • $248M net revenues • Collaboration with Zai Lab in China • National reimbursement in Sweden NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancerABOUT US - NOVOCURE
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. LEADERSHIP - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.NOVOCURE
Novocure. Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. This site allows you to submit a proposal (s) seeking Independent Medical Educational Grants and CharitableContributions.
NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVEOPTUNE MEDICARE COVERAGENOVOCURE OPTUNE DEVICENOVOCURE ISRAELNOVOCURE LOCATIONSNOVOCURE MALVERN PANOVOCURE WIKIPEDIA ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per NCCN GUIDELINES RECOMMEND NOVOCURE'S GBM THERAPY INNCCN GUIDELINES 2020 AMLNCCN GUIDELINES COLON CANCER 2019 Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide NOVOCURE | THERAPY FOR SOLID TUMORS CALLED TUMOR TREATINGABOUT USOUR THERAPYOUR PIPELINEPATIENT-FORWARDNEWS AND MEDIAINVESTOR RELATIONS the story of Novocure. We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancerABOUT US - NOVOCURE
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. CONTACT US - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.SEC FILINGS
about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. LEADERSHIP - NOVOCURE about us. corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.; corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.CAREERS - NOVOCURE
Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.NOVOCURE
Novocure. Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes. This site allows you to submit a proposal (s) seeking Independent Medical Educational Grants and CharitableContributions.
NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read More NOVOCURE ANNOUNCES THAT THE MEDICARE DME MACS HAVEOPTUNE MEDICARE COVERAGENOVOCURE OPTUNE DEVICENOVOCURE ISRAELNOVOCURE LOCATIONSNOVOCURE MALVERN PANOVOCURE WIKIPEDIA ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per NCCN GUIDELINES RECOMMEND NOVOCURE'S GBM THERAPY INNCCN GUIDELINES 2020 AMLNCCN GUIDELINES COLON CANCER 2019 Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomideOUR PIPELINE
The science of Tumor Treating Fields has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 20 years. We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancercells.
ANNUAL REPORTS
annual reports. annual. reports. See our business highlights, and hear from our Executive Chairman William Doyle and CEO Asaf Danziger in our2020
PATIENT FORWARD
patient. forward. Patients remain at the heart of the work we do every day. Patients’ health. Patients’ lives. Patients’ families and caregivers. They are what matters most to us, guiding us forward in our goal to deliver a completely different cancer therapy that could lengthen patient lives while maintaining their quality of life. NOVOCURE ANNOUNCES UPDATE ON PHASE 3 PIVOTAL LUNAR TRIAL Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR NOVOCURE INITIATES PHASE 3 PIVOTAL TRIAL IN RECURRENT ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trialinitiated to
NOVOCURE LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on Read MoreCAREERS AT NOVOCURE
Shift Type. Reset. Senior Regulatory Affairs Specialist. Senior Regulatory Affairs Specialist Haifa, IL, 3508504 Regulatory/Safety Jun 1, 2021. Haifa, IL, 3508504. Regulatory/Safety. Full Time. Logistic and Office Administrator. Logistic and Office Administrator Haifa, IL, 3508504 Supply Chain Jun 1, 2021. FIRST PATIENT ENROLLED IN NOVOCURE’S EF-33 PHASE 2 PILOT EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients NCCN GUIDELINES RECOMMEND NOVOCURE'S GBM THERAPY IN Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as RESULTS FROM STELLAR TRIAL OF TUMOR TREATING FIELDS WITH STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced We have revised our Privacy Policy that is in effect as of May 25, 2018. Please click here to access it.* __
* __
* Search
* Contact Us
* Careers
* External Funding
* News and Media
__
* about us
corporate timeline
Professor
Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.ESG report
Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.* our therapy
* our pipeline
clinical trials
Our mechanism
of action is broadly applicable across a variety of solid tumors. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.* patient-forward
* news and media
press releases
press kits
media gallery
featured stories
* investor relationspress releases
corporate presentationevents
annual reports
sec filings
stock information
corporate governancefaq
email alerts
NASDAQ: CURRENT STOCK PRICE205.71
0.62
last update 6/4/2021 16:00pm* careers
our locations
current job listings__ __
FIRST PATIENT ENROLLEDIN TRIDENT
The first patient has been enrolled in our global phase 3 TRIDENT trial in newly diagnosed glioblastoma.Learn more
KEYNOTE-B36
IDE APPROVAL
The FDA has approved our investigational device exemption application to initiate the KEYNOTE-B36 trial evaluating TTFields together with pembrolizumab in NSCLC, conducted in collaboration with MSD. We also announced the formation of a scientific steering committee.Learn more
UPDATE ON
LUNAR TRIAL
We announced an update regarding our phase 3 pivotal LUNAR trial of Tumor Treating Fields as a treatment for stage 4 non-small cell lung cancer following platinum failure.Learn more
NOVOCURE AT
AACR ANNUAL MEETING
This year’s American Association for Cancer Research Annual Meeting will highlight 26 presentations suggesting broad applicability of Tumor Treating Fields.Learn more
FIRST PATIENT ENROLLEDIN TRIDENT
The first patient has been enrolled in our global phase 3 TRIDENT trial in newly diagnosed glioblastoma.Learn more
KEYNOTE-B36
IDE APPROVAL
The FDA has approved our investigational device exemption application to initiate the KEYNOTE-B36 trial evaluating TTFields together with pembrolizumab in NSCLC, conducted in collaboration with MSD. We also announced the formation of a scientific steering committee.Learn more
MECHANISM OF ACTION
MECHANISM OF ACTION
Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division.JOIN OUR TEAM
JOIN OUR TEAM
We count on our talented team members who are committed to our mission of striving to extend survival in some of the most aggressive forms ofcancer.
NEWS AND MEDIA
NEWS AND MEDIA
See what we’ve been up to and access materials related to our company, our people and our therapy.Press Releases
THE STORY
OF NOVOCURE
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.Learn More
WE CAN LEVERAGE PHYSICS TO FIGHT CANCER Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division.OUR THERAPY
EXPLORE OUR CLINICAL PIPELINE Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight invivo tumor models.
OUR PIPELINE
WE ARE DEDICATED TO MAKING A DIFFERENCE IN CANCER Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.PATIENT-FORWARD
__
* about us
* corporate timeline* leadership
* corporate presentation* ESG report
* our therapy
* our pipeline
* clinical trials
* novocuretrial.com
* patient-forward
* news and media
* press releases
* press kits
* media gallery
* featured stories
* investor relations* press releases
* corporate presentation* events
* annual reports
* sec filings
* stock information
* corporate governance* faq
* email alerts
* careers
* our locations
* current job listings * Corporate Compliance * California Consumer Privacy Notice * Website Privacy Policy * HIPAA Privacy Notice * Terms and Conditions* Site Map
* Novocure Vulnerability Disclosure Process * DATA PRIVACY POLICY – NOVOCURE.COM On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Patient images reflect the health status of the patients at the time each photo or video was taken. © 2021 Novocure GmbH – all rights reservedCOOKIE POLICY
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policyor
visit www.allaboutcookies.org .* about us
* corporate timelineProfessor
Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones. * leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. * corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.* ESG report
Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.* our therapy
* our pipeline
* clinical trials
Our mechanism
of action is broadly applicable across a variety of solid tumors. * novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.* patient-forward
* news and media
* press releases
* press kits
* media gallery
* featured stories
* investor relations* press releases
* corporate presentation* events
* annual reports
* sec filings
* stock information
* corporate governance* faq
* email alerts
* careers
* our locations
* current job listings* __
* __
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0